{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:36:19Z","timestamp":1790620579454,"version":"4.1.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint protein B7-H3 (CD276) has garnered increasing attention as a cancer immunotherapy target. Despite the absence of a definitively identified receptor, B7-H3 is implicated in multiple mechanisms of tumor progression. As a cancer biomarker, it is overexpressed in numerous cancer types and is often associated with poor prognosis. B7-H3 is currently the target of numerous immunotherapeutic strategies, and clinical trials are underway in various cancer types. This review provides an updated summary of the current body of knowledge regarding immune checkpoint protein B7-H3 and cancer therapies targeting it, highlighting its demonstrated promise as a cancer immunotherapy target, the need for further investigation into the regulation and mechanisms of B7-H3 and its associated pathways, and therapeutic progress.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1857767","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:44:12Z","timestamp":1784267052000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["B7-H3 (CD276): an actionable therapeutic target and prognostic biomarker across human malignancies"],"prefix":"10.3389","volume":"17","author":[{"given":"Dayna","family":"Smith","sequence":"first","affiliation":[{"name":"Research Institute of Molecular Pathology","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anudishi","family":"Tyagi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University","place":["Richmond, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Lokesh","family":"Battula","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Massey Comprehensive Cancer Center, Virginia Commonwealth University","place":["Richmond, VA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.03.014","article-title":"Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy","volume":"86","author":"Gaikwad","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.169.3950.1042","article-title":"A theory of self-nonself discrimination","volume":"169","author":"Bretscher","year":"1970","journal-title":"Sci (American Assoc For Advancement Science)"},{"key":"B8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/gb-2005-6-6-223","article-title":"The B7 family of immune-regulatory ligands","volume":"6","author":"Collins","year":"2005","journal-title":"Genome Biol"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1038\/nri727","article-title":"The B7\u2013CD28 superfamily","volume":"2","author":"Sharpe","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-385591","article-title":"The role of B7 family molecules in hematologic Malignancy","volume":"121","author":"Greaves","year":"2013","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.03.003","article-title":"Structure and T cell inhibition properties of B7 family member, B7-H3","volume":"21","author":"Vigdorovich","year":"2013","journal-title":"Structure"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/85339","article-title":"B7-H3: A costimulatory molecule for T cell activation and IFN-\u03b3 production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014671","article-title":"Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML","volume":"139","author":"Tyagi","year":"2022","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.1582","article-title":"The immunoglobulin fold","volume":"242","author":"Bork","year":"1994","journal-title":"J Mol Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.12.6294","article-title":"Characterization of mouse and human B7-H3 genes","volume":"168","author":"Sun","year":"2002","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1399-0039.2007.00853.x","article-title":"4IgB7\u2010H3 is the major isoform expressed on immunocytes as well as Malignant cells","volume":"70","author":"Zhou","year":"2007","journal-title":"Tissue Antigens"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2584","article-title":"B7-H3: An attractive target for antibody-based immunotherapy","volume":"27","author":"Kontos","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.02.010","article-title":"An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers","volume":"31","author":"Zekri","year":"2023","journal-title":"Mol Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2007.02723.x","article-title":"Soluble CD276 (B7\u2010H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum","volume":"123","author":"Zhang","year":"2008","journal-title":"Immunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3233\/cbm-210178","article-title":"Evaluation of the role of soluble B7-H3 in association with membrane B7-H3 expression in gastric adenocarcinoma - PubMed","volume":"33","author":"Huang","year":"2022","journal-title":"Cancer Biomarkers: Section A Dis Markers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076965","article-title":"Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma","volume":"8","author":"Chen","year":"2013","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10169","DOI":"10.1038\/s41598-026-40855-2","article-title":"sB7-H3 as a prognostic biomarker in osteosarcoma: Insights into clinical outcomes","volume":"16","author":"Zhao","year":"2026","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243379","article-title":"Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer","volume":"15","author":"Azuma","year":"2020","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7150\/thno.123285","article-title":"Anti-cancer immune priming with \u03b2-radioligand therapy using a novel high affinity antibody selectively targeting the 4Ig-isoform of B7-H3","volume":"16","author":"Glazer","year":"2026","journal-title":"Theranostics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s42003-023-05736-8","article-title":"Dimerization of the 4Ig isoform of B7-H3 in tumor cells mediates enhanced proliferation and tumorigenic signaling","volume":"7","author":"Sutton","year":"2024","journal-title":"Commun Biol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.coi.2009.01.009","article-title":"TREM and TREM-like receptors in inflammation and disease","volume":"21","author":"Ford","year":"2009","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100534","article-title":"TLT2 potentiates neutrophil antibacterial activity and chemotaxis in response to G protein-coupled receptor-mediated signaling","volume":"187","author":"Halpert","year":"2011","journal-title":"J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802423105","article-title":"Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses","volume":"105","author":"Hashiguchi","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839028","article-title":"B7\u2010H3 is a potent inhibitor of human T\u2010cell activation: No evidence for B7\u2010H3 and TREML2 interaction","volume":"39","author":"Leitner","year":"2009","journal-title":"Eur J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz451.008","article-title":"A platform for extracellular interactome discovery identifies novel functional binding partners for the immune receptors B7-H3\/CD276 and PVR\/CD155","volume":"18","author":"Husain","year":"2019","journal-title":"Mol Cell Proteomics"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45280","article-title":"IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer","volume":"11","author":"Gao","year":"2021","journal-title":"Theranostics"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.724655","article-title":"Super-enhancer induced IL-20RA promotes proliferation\/metastasis and immune evasion in colorectal cancer","volume":"11","author":"Yu","year":"2021","journal-title":"Front Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax3160","article-title":"B7-H3\u00d74-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+ tumor-infiltrating lymphocytes","volume":"7","author":"You","year":"2021","journal-title":"Sci Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2014.03.003","article-title":"PLA2R1: Expression and function in cancer","volume":"1846","author":"Bernard","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/s41419-021-03468-3","article-title":"PLA2R1 promotes DNA damage and inhibits spontaneous tumor formation during aging","volume":"12","author":"Huna","year":"2021","journal-title":"Cell Death Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2025451118","article-title":"A membrane protein display platform for receptor interactome discovery","volume":"118","author":"Cao","year":"2021","journal-title":"Proc Natl Acad Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"vdac098","DOI":"10.1093\/noajnl\/vdac098","article-title":"AAMP is a binding partner of costimulatory human B7-H3","volume":"4","author":"Ciprut","year":"2022","journal-title":"Neuro-Oncology Adv"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0805458105","article-title":"The contrasting role of B7-H3","volume":"105","author":"Hofmeyer","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/s41467-023-36881-7","article-title":"mTORC1 upregulates B7-H3\/CD276 to inhibit antitumor T cells and drive tumor immune evasion","volume":"14","author":"Liu","year":"2023","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02683-9","article-title":"B7-H3 is spliced by SRSF3 in colorectal cancer","volume":"70","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.108956","article-title":"N6-methyladenosine modification of B7-H3 mRNA promotes the development and progression of colorectal cancer","volume":"27","author":"Chen","year":"2024","journal-title":"iScience"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.03.010","article-title":"B7-H3 in cancer \u2013 beyond immune regulation","volume":"4","author":"Flem-Karlsen","year":"2018","journal-title":"Trends Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-08-4517","article-title":"MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: Potential implications for immune based therapy of human solid tumors","volume":"69","author":"Xu","year":"2009","journal-title":"Cancer Res"},{"key":"B45","article-title":"Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors1","volume":"61","author":"Modak","year":"2001","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: From immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41419-024-06791-7","article-title":"The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma","volume":"15","author":"Pathania","year":"2024","journal-title":"Cell Death Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3390\/bioengineering12121344","article-title":"Exploiting B7-H3: Molecular insights and immunotherapeutic strategies for osteosarcoma","volume":"12","author":"Xie","year":"2025","journal-title":"Bioengineering (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0405025101","article-title":"Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis","volume":"101","author":"Castriconi","year":"2004","journal-title":"Proc Natl Acad Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1038\/s41467-021-22618-x","article-title":"FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer","volume":"12","author":"Huang","year":"2021","journal-title":"Nat Commun"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1516991112","article-title":"Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response","volume":"112","author":"Chen","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.9.5445","article-title":"B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells","volume":"173","author":"Luo","year":"2004","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1\u2013mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2017.90","article-title":"Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function","volume":"27","author":"Lee","year":"2017","journal-title":"Cell Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1538","article-title":"Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1\u03b1","volume":"76","author":"Lim","year":"2016","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6935","article-title":"Cancer cell-expressed B7-H3 regulates the differentiation of tumor-associated macrophages in human colorectal carcinoma","volume":"14","author":"Mao","year":"2017","journal-title":"Oncol Lett"},{"key":"B57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4284","article-title":"Integrated analysis reveals distinct molecular, clinical, and immunological features of B7\u2010H3 in acute myeloid leukemia","volume":"10","author":"Zhang","year":"2021","journal-title":"Cancer Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1158\/2326-6066.cir-21-0407","article-title":"B7-H3 suppresses antitumor immunity via the CCL2\u2013CCR2\u2013M2 macrophage axis and contributes to ovarian cancer progression","volume":"10","author":"Miyamoto","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.cd-21-1059","article-title":"Hallmarks of cancer: New dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0331-6","article-title":"B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src\/STAT3 and c-Cbl-mediated degradation of SOCS3","volume":"33","author":"Lin","year":"2019","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-11-0072","article-title":"B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2\/Stat3 phosphorylation","volume":"10","author":"Liu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s222224","article-title":"&lt;p&gt;B7-H3 induces ovarian cancer drugs resistance through an PI3K\/AKT\/BCL-2 signaling pathway&lt;\/p&gt;","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manage Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2139\/ssrn.3449325","article-title":"B7-H3 promotes colorectal cancer angiogenesis through activating the NF-\u03baB pathway to induce VEGFA expression","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110737","article-title":"Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1\/mTOR\/VEGFA pathway","volume":"109","author":"Wu","year":"2023","journal-title":"Cell Signal"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-019-09084-w","article-title":"B7-H3 modulates endothelial cell angiogenesis through the VEGF cytokine","volume":"67","author":"Lai","year":"2019","journal-title":"Immunol Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0546","article-title":"Pan-cancer interrogation of B7-H3 (CD276) as an actionable therapeutic target across human Malignancies","volume":"4","author":"Miller","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-015-0195-z","article-title":"B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2\/STAT3\/Slug signaling pathway","volume":"15","author":"Kang","year":"2015","journal-title":"Cancer Cell Int"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s222224","article-title":"B7-H3 induces ovarian cancer drugs resistance through an PI3K\/AKT\/BCL-2 signaling pathway","volume":"11","author":"Zhou","year":"2019","journal-title":"Cancer Manag Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.canlet.2018.05.015","article-title":"Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins","volume":"431","author":"Yang","year":"2018","journal-title":"Cancer Lett"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2018.1461304","article-title":"Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma","volume":"7","author":"Zhang","year":"2018","journal-title":"OncoImmunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13744","article-title":"Genetic and clinical characterization of B7\u2010H3 (CD276) expression and epigenetic regulation in diffuse brain glioma","volume":"109","author":"Wang","year":"2018","journal-title":"Cancer Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2022.2095285","article-title":"DNA methylation and mRNA expression of B7-H3 gene in ankylosing spondylitis: A case-control study","volume":"51","author":"Chen","year":"2022","journal-title":"Immunol Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1116805","DOI":"10.3389\/fcell.2023.1116805","article-title":"Epigenetic reprogramming in cancer: From diagnosis to treatment","volume":"11","author":"Costa","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs22-p2-20-06","article-title":"Abstract P2-20-06: Anti-B7-H3 antibody (T-1A5) blocks immunomodulatory function of B7-H3 and enhances NK and T cell\u2013mediated cytotoxicity against breast cancer cells","volume":"83","author":"Anand","year":"2023","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3611","article-title":"Differential expression of 2IgB7-H3 and 4IgB7-H3 in cancer cell lines and glioma tissues","volume":"10","author":"Wang","year":"2015","journal-title":"Oncol Lett"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1481649","article-title":"Expression characteristic of 4Ig B7-H3 and 2Ig B7-H3 in acute myeloid leukemia","volume":"12","author":"Zhang","year":"2021","journal-title":"Bioengineered"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114890","article-title":"B7-H3 immunoregulatory roles in cancer","volume":"163","author":"Mortezaee","year":"2023","journal-title":"Biomedicine pharmacotherapy"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(08)60301-8","article-title":"B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome","volume":"104","author":"Zang","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00331-6","article-title":"Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer","volume":"24","author":"Amori","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m115.679852","article-title":"Humanized affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3 *","volume":"290","author":"Ahmed","year":"2015","journal-title":"J Biol Chem"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-0715","article-title":"Development of an Fc-enhanced anti\u2013B7-H3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.21417\/es2023nm","article-title":"Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial","volume":"29","author":"Shenderov","year":"2023","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004424","article-title":"Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I\/II trial","volume":"10","author":"Aggarwal","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1111\/cas.12915","article-title":"Development of <scp>DS<\/scp>\u20105573a: A novel afucosylated <scp>mA<\/scp>b directed at B7\u2010H3 with potent antitumor activity","volume":"107","author":"Nagase\u2010Zembutsu","year":"2016","journal-title":"Cancer Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100364","article-title":"LBA3 compartmental radioimmunotherapy (cRIT) 131I-OMBURTAMAB in patients with neuroblastoma (NB) central nervous system (CNS) and\/or leptomeningeal (LM) metastases: Updated results from pivotal trial 101","volume":"16","author":"Basu","year":"2022","journal-title":"Immuno-Oncology Technol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-022-01383-4","article-title":"Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS Malignancies","volume":"15","author":"Kramer","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30322-x","article-title":"Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial","volume":"19","author":"Souweidane","year":"2018","journal-title":"Lancet Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.nucmedbio.2017.01.003","article-title":"B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models","volume":"47","author":"Kasten","year":"2017","journal-title":"Nucl Med Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8550","article-title":"Therapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibody","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"B94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nucmedbio.2017.12.004","article-title":"212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models","volume":"58","author":"Kasten","year":"2018","journal-title":"Nucl Med Biol"},{"key":"B95","article-title":"Erratum to: Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma","volume":"28","year":"2026","journal-title":"Neuro Oncol"},{"key":"B96","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf039","article-title":"Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma","volume":"27","author":"Souweidane","year":"2025","journal-title":"Neuro Oncol"},{"key":"B97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009110","article-title":"Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity","volume":"12","author":"Meeus","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3390\/pharmaceutics14091780","article-title":"Evaluation of an affibody-based binder for imaging of immune check-point molecule B7-H3","volume":"14","author":"Oroujeni","year":"2022","journal-title":"Pharmaceutics"},{"key":"B99","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.5c00320","article-title":"Preclinical positron emission tomography imaging of B7-H3 expression using affibody molecules labeled with gallium-68","volume":"8","author":"Tolmachev","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-20-0116","article-title":"Preclinical development of MGC018, a duocarmycin-based antibody\u2013drug conjugate targeting B7-H3 for solid cancer","volume":"19","author":"Scribner","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007174","article-title":"Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma","volume":"11","author":"Brignole","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B102","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41419-025-08397-z","article-title":"The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models","author":"Bianchi","year":"2026","journal-title":"Cell Death Dis"},{"key":"B103","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1200\/JCO.2023.41.16_suppl.3017","article-title":"ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3\u2013targeting antibody-drug conjugate, in patients with advanced solid tumor","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2024-193405","article-title":"Anti-leukemia combinatorial efficacy of ABBV155, a B7H3-BCL-XL inhibitor antibody-drug conjugate, in combination with venetoclax through BCL-XL\/BIM and BCL-2\/BIM complex dissociations","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-21-0554","article-title":"DS-7300a, a DNA topoisomerase I inhibitor, DXd-based antibody\u2013drug conjugate targeting B7-H3, exerts potent antitumor activities in preclinical models","volume":"21","author":"Yamato","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B106","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.1876","article-title":"690P Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with advanced solid tumors: Updated clinical and biomarker results from a phase I\/II study","volume":"34","author":"Patel","year":"2023","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"crossref","DOI":"10.1080\/14796694.2025.2565995","article-title":"IDeate-Lung02: a Phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","volume":"21","author":"Owonikoko","year":"2025","journal-title":"Future Oncol"},{"key":"B108","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I\/II study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann Oncol"},{"key":"B109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol"},{"key":"B110","article-title":"Results from a phase 1\/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3390\/cancers15041189","article-title":"Modulating T cell responses by targeting CD3","volume":"15","author":"Menon","year":"2023","journal-title":"Cancers"},{"key":"B112","doi-asserted-by":"crossref","first-page":"TPS2601","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2601","article-title":"A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors","volume":"36","author":"Shankar","year":"2018","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3390\/life12020157","article-title":"A novel anti-B7-H3 \u00d7 Anti-CD3 bispecific antibody with potent antitumor activity","volume":"12","author":"Feng","year":"2022","journal-title":"Life"},{"key":"B114","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.2c02850","article-title":"Multivalent, bispecific \u03b1B7-H3-\u03b1CD3 chemically self-assembled nanorings direct potent T cell responses against medulloblastoma","volume":"16","author":"Mews","year":"2022","journal-title":"ACS Nano"},{"key":"B115","doi-asserted-by":"crossref","DOI":"10.1038\/s41401-023-01118-2","article-title":"Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities","volume":"44","author":"Li","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"B116","article-title":"Abstract LB056: IBI334, a novel ADCC-enhanced B7-H3\/EGFR bispecific antibody, demonstrated potent pre-clinical efficacy in solid tumors","volume":"84","author":"Guan","year":"2024","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s40364-025-00872-1","article-title":"Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC","volume":"13","author":"Zhi","year":"2025","journal-title":"biomark Res"},{"key":"B118","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-2955","article-title":"Abstract 2955: Preclinical development of TJ101, a potent bispecific ADC targeting EGFR and B7-H3 for the treatment of solid cancers","volume":"85","author":"Qi","year":"2025","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-5087","article-title":"Abstract 5087: ILB-3101, a novel B7H3-targeting ADC with Eribulin as payload, demonstrates strong tumor killing activities and favorable PK\/TOX profile in preclinical evaluation","volume":"84","author":"Shang","year":"2024","journal-title":"Cancer Res"},{"key":"B120","article-title":"Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer","volume":"11","author":"Yang","year":"2020","journal-title":"Front Pharmacol"},{"key":"B121","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-25-A140","article-title":"Abstract A140: MGC026, a glycan-linked, exatecan-based antibody-drug conjugate (ADC) targeting B7-H3, is efficacious toward prostate cancer patient-derived xenografts","volume":"24","author":"Scribner","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1163136","article-title":"IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer","volume":"14","author":"Lutz","year":"2023","journal-title":"Front Immunol"},{"key":"B123","doi-asserted-by":"crossref","DOI":"10.1186\/2051-1426-3-S2-O8","article-title":"Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3","volume":"3","author":"Powderly","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B124","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01974","article-title":"B7H3-directed intraperitoneal radioimmunotherapy with radioiodinated omburtamab for desmoplastic small round cell tumor and other peritoneal tumors: results of a phase I study","volume":"38","author":"Modak","year":"2020","journal-title":"J Clin Oncol"},{"key":"B125","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1133","article-title":"620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion","volume":"32","author":"Shenderov","year":"2021","journal-title":"Ann Oncol"},{"key":"B126","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.2631","article-title":"Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors","volume":"39","author":"Jang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B127","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.3027","article-title":"Mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed\/refractory solid tumors: Dose expansion results","volume":"41","author":"Carneiro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5051","article-title":"Promising early results of MHB088C (B7-H3 ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) from a phase 1\/2 multicenter study","volume":"43","author":"Shen","year":"2025","journal-title":"J Clin Oncol"},{"key":"B129","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.8510","article-title":"Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1\/2 multicenter study","volume":"43","author":"Shen","year":"2025","journal-title":"J Clin Oncol"},{"key":"B130","article-title":"Results from a phase 1\/2 study of 7MW3711: A novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with advanced solid tumors","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B131","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-0750","article-title":"Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety","volume":"13","author":"Vitanza","year":"2023","journal-title":"Cancer Discov"},{"key":"B132","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.23.02229","article-title":"STRIvE-02: A first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857767\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:44:21Z","timestamp":1784267061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1857767\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":132,"alternative-id":["10.3389\/fimmu.2026.1857767"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1857767","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"article-number":"1857767"}}